Shield Therapeutics PLC (LON:STX) insider Carl Sterritt purchased 88,235 shares of the firm’s stock in a transaction that occurred on Friday, September 21st. The shares were bought at an average cost of GBX 34 ($0.44) per share, with a total value of £29,999.90 ($39,077.63).
Shares of LON STX opened at GBX 34 ($0.44) on Thursday. Shield Therapeutics PLC has a 1-year low of GBX 15 ($0.20) and a 1-year high of GBX 168.50 ($2.19).
STX has been the subject of several recent research reports. Peel Hunt reaffirmed an “under review” rating on shares of Shield Therapeutics in a report on Thursday, May 31st. Liberum Capital reaffirmed an “under review” rating on shares of Shield Therapeutics in a report on Monday, July 23rd.
About Shield Therapeutics
Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease.
Featured Story: Google Finance Portfolio Workaround
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.